Research programme: antibody therapeutics - Innovative Targeting Solutions/Janssen Biotech

Drug Profile

Research programme: antibody therapeutics - Innovative Targeting Solutions/Janssen Biotech

Alternative Names: HuTARG antibodies - Innovative Targeting Solutions/Janssen Biotech

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovative Targeting Solutions
  • Developer Innovative Targeting Solutions; Janssen Biotech
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 07 Sep 2016 Innovative Targeting Solutions has patent protection for HuTARG™ technology in USA (Innovative Targeting Solutions website, September 2016)
  • 23 Aug 2016 Early research in Autoimmune disorders in USA and Canada (Parenteral)
  • 23 Aug 2016 Early research in Cancer in USA and Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top